Baseline patient characteristics
| Characteristic | Hysteroscopy within 180 days prior to hysterectomy | P -value* | |
| No (n=698) | Yes (n=133) | ||
| Age at surgery (years), mean (SD) | 67.8 (10.6) | 67.7 (11.1) | 0.96 |
| BMI (kg/m2), mean (SD) | 31.3 (8.0) | 31.6 (7.5) | 0.78 |
| ASA score | 0.52 | ||
| 1–2 | 429 (61.5%) | 86 (64.7%) | |
| 3–4 | 266 (38.1%) | 47 (35.3%) | |
| Not documented | 3 (0.4%) | 0 (0.0%) | |
| FIGO stage (2009) | 0.045 | ||
| IA | 295 (42.3%) | 67 (50.4%) | |
| IB | 80 (11.5%) | 24 (18.0%) | |
| II | 17 (2.4%) | 2 (1.5%) | |
| IIIA/B | 32 (4.6%) | 4 (3.0%) | |
| IIIC | 121 (17.3%) | 14 (10.5%) | |
| IV | 153 (21.9%) | 22 (16.5%) | |
| Histology | 0.21 | ||
| Endometrioid† | 225 (32.3%) | 43 (32.3%) | |
| Serous | 313 (44.8%) | 53 (39.8%) | |
| Clear cell | 67 (9.6%) | 13 (9.8%) | |
| Other non-endometrioid | 55 (7.9%) | 9 (6.8%) | |
| Mixed | 37 (5.3%) | 14 (10.5%) | |
| Not documented | 1 (0.1%) | 1 (0.8%) | |
| Tumor diameter (mm) | 0.07 | ||
| ≤2 cm | 124 (17.8%) | 33 (24.8%) | |
| >2 cm | 556 (79.7%) | 98 (73.7%) | |
| Not documented | 18 (2.6%) | 2 (1.5%) | |
| Lymphovascular space invasion | 0.44 | ||
| No | 456 (65.3%) | 92 (69.2%) | |
| Yes | 238 (34.1%) | 41 (30.8%) | |
| Not documented | 4 (0.6%) | 0 (0.0%) | |
| Myometrial invasion | 0.95 | ||
| None | 148 (21.2%) | 29 (21.8%) | |
| <50% | 288 (41.3%) | 53 (39.8%) | |
| ≥50% | 262 (37.5%) | 51 (38.3%) | |
| Cervical stromal invasion | 0.23 | ||
| No | 608 (87.1%) | 121 (91.0%) | |
| Yes | 89 (12.8%) | 12 (9.0%) | |
| Unknown | 1 (0.1%) | 0 (0.0%) | |
| Adnexal involvement | 0.10 | ||
| No | 573 (82.1%) | 117 (88.0%) | |
| Yes | 125 (17.9%) | 16 (12.0%) | |
| Type of adjuvant therapy | 0.31 | ||
| None | 152 (21.8%) | 33 (24.8%) | |
| VB only | 177 (25.4%) | 41 (30.8%) | |
| Chemotherapy±VB | 210 (30.1%) | 37 (27.8%) | |
| Chemotherapy and EBRT±VB | 87 (12.5%) | 11 (8.3%) | |
| EBRT only | 18 (2.6%) | 6 (4.5%) | |
| EBRT and VB | 6 (0.9%) | 0 (0.0%) | |
| Not documented | 48 (6.9%) | 5 (3.8%) | |
*Each characteristic was compared between the groups using the two-sample t-test for age and BMI, and the chi-square test for all categorical variables. Patients with an unknown or not documented characteristic were ignored for the statistical comparison of that specific characteristic.
†Endometrioid includes endometrioid, mucinous, squamous, and adenocarcinoma not specified.
ASA, American Society of Anesthesiologists; BMI, body mass index; EBRT, external beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation; VB, vaginal brachytherapy.